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Dietary iron restriction alleviates 
renal tubulointerstitial injury 
induced by protein overload in mice
Yasumasa Ikeda1, Yuya Horinouchi1, Hirofumi Hamano1,2, Tasuku Hirayama3, Seiji Kishi4, 
Yuki Izawa-Ishizawa  1, Masaki Imanishi2, Yoshito Zamami  2,5, Kenshi Takechi6, Licht 
Miyamoto7, Keisuke Ishizawa2,5, Ken-ichi Aihara8, Hideko Nagasawa3, Koichiro Tsuchiya7 & 
Toshiaki Tamaki1
Increased proteinuria causes tubulointerstitial injury due to inflammation in chronic kidney disease 
(CKD). Iron restriction exhibits protective effects against renal dysfunction; however, its effects against 
protein overload-induced tubulointerstitial damage remain unclear. Here, we investigated dietary iron 
restriction effect on tubulointerstitial damage in mice with protein-overload tubulointerstitial injury. 
Renal tubulointerstitial injury in animal model was induced by intraperitoneal injection of an overdose 
of bovine serum albumin (BSA). We divided mice into three groups: normal saline + normal diet (ND), 
BSA + ND, and BSA + iron-restricted diet (IRD). BSA overload induced renal tubulointerstitial injury 
in the ND mice, which was ameliorated in the IRD mice. Inflammatory cytokines and extracellular 
matrix mRNA expression was upregulated in BSA + ND mice kidneys and was inhibited by IRD. BSA-
induced increase in renal superoxide production, NADPH oxidase activity, and p22phox expression was 
diminished in the IRD mice. IRD suppression increased BSA-induced renal macrophage infiltration. 
Moreover, BSA mice exhibited nucleotide-binding oligomerisation domain-like receptor pyrin domain-
containing protein (NLRP) inflammasome activation, which was inhibited by IRD. Ferrous iron increased 
in kidneys with BSA overload and was inhibited by IRD. Thus, iron restriction inhibited oxidative 
stress and inflammatory changes, contributing to the protective effect against BSA overload-induced 
tubulointerstitial injury.
The number of patients with chronic kidney disease (CKD) has been increasing worldwide, and the presence of 
CKD worsens morbidity and mortality. Proteinuria, including albuminuria, is a biomarker for CKD, is associated 
with renal tubular and tubulointerstitial damage, and causes further progression of kidney injury and deteriora-
tion of renal function1, 2. Proteinuria induces tubulointerstitial injury through apoptosis3, inflammation4, epithe-
lial–mesenchymal transition5, and oxidative stress6. Recent studies have demonstrated that nucleotide-binding 
oligomerisation domain-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome also plays a 
crucial role in the progression of tubulointerstitial damage induced by protein overload7, 8. Thus, proteinuria is 
involved in further exacerbation of CKD through various contributing factors.
Iron is an essential trace metal for metabolic processes and enzyme activity in all living organisms. 
Moreover, iron catalyses the Fenton reaction and consequently causes oxidative stress via hydroxyl radical 
production9. Therefore, intracellular iron is restrictively controlled by iron transporters, iron-binding proteins, 
and iron-storage proteins10. Of late, it has been demonstrated that the kidney participates in the regulation of 
1Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, 
Tokushima, Japan. 2Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan. 3Laboratory of 
Pharmaceutical and Medicinal Chemistry, Gifu Pharmaceutical University, Gifu, Japan. 4Department of Nephrology, 
Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 5Department of 
Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, 
Tokushima, Japan. 6Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, 
Japan. 7Department of Medical Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate 
School, Tokushima, Japan. 8Department of Community Medicine for Diabetes and Metabolic Disorders, Institute of 
Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. Correspondence and requests for 
materials should be addressed to Y.I. (email: yasuike@tokushima-u.ac.jp)
Received: 9 May 2017
Accepted: 14 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNTIfIC REPORTS | 7: 10621  | DOI:10.1038/s41598-017-11089-0
iron metabolism and homeostasis11; therefore, iron is potentially involved in renal pathophysiology. In differ-
ent experimental animal models, iron is involved in determining the pathological condition of CKD such as 
diabetic nephropathy12–14, hypertensive kidney injury15, 16, and renal fibrosis17, and these diseases are amelio-
rated by iron reduction in the body. Dietary iron restriction inhibits the increment of urinary albuminuria in 
db/db mice12; however, it remains unclear whether iron restriction can prevent protein overload-induced renal 
injury.
In the present study, we determined that dietary iron restriction alleviates protein overload-induced tubuloin-
terstitial injury, and inhibits oxidative stress and inflammatory changes in mice. Moreover, ferrous iron produc-
tion is elevated in the kidneys with protein overload, suggesting its involvement in the pathological condition of 
protein-overload renal injury through oxidative stress via the Fenton reaction.
Results
Effects of dietary iron restriction on BSA-induced tubulointerstitial injury. Renal tubulointer-
stitial injury was induced in mice with BSA overload, and it was alleviated by dietary iron restriction (Fig. 1a 
(upper) and b). Similar to histological analysis, the mRNA expression of lipocalin-2, a marker of tubulointerstitial 
damage, was also upregulated in BSA-overload mice, which was inhibited by iron-restricted diet (IRD, Fig. 1c). 
BSA-induced upregulation of fibrosis-related genes, such as collagen 1 and fibronectin, was also suppressed in 
mice with IRD (Fig. 1a (middle and lower), and d). These results suggested the favourable effect of dietary iron 
restriction in protein-overload tubulointerstitial injury.
Dietary iron restriction attenuates the BSA-induced renal inflammatory changes. BSA aug-
mented renal inflammatory cytokines, including TNF-α, MCP-1, IL-6, and PAI-1, which were abolished by iron 
restriction (Fig. 2a). Increment of macrophage infiltration in the tubulointerstitium and increased F4/80 mRNA 
expression was observed in mice with BSA overload and was reduced by IRD (Fig. 2b–d).
BSA-induced renal oxidative stress was reduced by iron restriction. BSA promotes oxidative stress 
production through NADPH oxidase-dependent pathway6. We performed dihydroethidium (DHE) staining 
to assess oxidative stress production. BSA-induced renal oxidative stress in mice kidneys was reduced by IRD 
(Fig. 3a and b). The increase in NADPH oxidase activity was elevated in the BSA + ND group mice kidneys and 
Figure 1. Dietary iron restriction inhibits BSA-induced tubulointerstitial injury. (a) Representative 
haematoxylin and eosin staining (HE), and immunohistochemical analysis of collagen 1 and fibronectin of the 
kidney section in the vehicle-injected and BSA-injected mice with normal diet (ND) or iron-restricted diet 
(IRD). (Arrow, atrophy and flattened tubule; Asterisk, tubular dilatation) (b) Quantitative analysis of interstitial 
damage scores. Values are expressed as mean ± SD. *P < 0.05, **P < 0.01; n = 8 in each group. The mRNA 
expression levels of (c) lipocalin-2, (d) collagen 1, and fibronectin in the kidneys of mice in each group. Values 
are expressed as mean ± SD. *P < 0.05, **P < 0.01, n = 6–9 in each group.
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Figure 2. Iron restriction prevents BSA-induced inflammatory changes. (a) Quantitative analysis of 
mRNA expression for inflammation-related genes in the kidneys of mice in each group. Values are 
expressed as mean ± SD. *P < 0.05, **P < 0.01, n = 6–9 in each group. (b) Representative figures of F4/80 
immunohistochemical staining in the kidney. (c) Semiquantitative analysis of the F4/80-positive spot in the 
kidneys of mice in each group. Values are expressed as mean ± SD. *P < 0.05, **P < 0.01, n = 8 in each group. 
(d) Quantification of F4/80 mRNA in the kidneys of mice in each group. Values are expressed as mean ± SD. 
*P < 0.05, **P < 0.01, n = 8 in each group.
Figure 3. Inhibitory effect of iron restriction against BSA-induced oxidative stress in the kidney. (a) 
Representative images of dihydroethidium (DHE) staining in the kidneys of mice in each group. (b) 
Semiquantitative analysis of fluorescence intensity. Values are expressed as mean ± SD, *P < 0.05, **P < 0.01, 
n = 8 in each group. (c) NADPH activity in the kidney. Values are expressed as mean ± SD, *P < 0.05, 
**P < 0.01, n = 8 in each group. (d) p22phox mRNA expression in the kidneys of mice in each group. Values 
are expressed as mean ± SD, *P < 0.05, **P < 0.01, n = 7–9 in each group. (e) p22phox protein expression in 
the kidney. Upper panel, representative figures of p22phox and β-actin from the kidney (full-length blots are 
presented as Supplementary Figure 1); and lower panel, semiquantitative analysis of densitometry for p22phox 
expression. Values are expressed as mean ± SD, *P < 0.05, **P < 0.01, n = 10–12 in each group.
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was inhibited by IRD (Fig. 3c). Both mRNA and protein expression of p22phox, a subunit of the NADPH oxidase 
complex, was augmented in the BSA + ND group mice kidneys and was inhibited in the BSA + IRD group mice 
(Fig. 3d).
NLRP3 inflammasome activation was abolished by dietary iron restriction. BSA + ND group 
mice exhibited upregulation of mRNA and protein expression of NLRP3, predominantly in the renal tubule, and 
this increase was diminished by IRD (Fig. 4a–d). Similarly, the expression of p10 caspase-1, ASC, and mature 
IL-1β was also upregulated by BSA overload and was inhibited by IRD (Fig. 4c and d).
Changes in iron content and ferrous iron in the kidney. Dietary iron restriction reduced renal iron 
content and induced mild anaemia in the mice with BSA overload. Although BSA overload did not alter the total 
iron content in the kidney compared to the vehicle group, renal ferrous iron was increased by BSA overload, and 
the increase was suppressed by IRD (Table 1 and Fig. 5).
Alteration of renal function and iron-related parameters in the mice with BSA overload. BSA 
overload resulted in an increase in the blood urea nitrogen (BUN) level, which was ameliorated by IRD. On the 
other hand, no change in the plasma creatinine level was observed between the three groups. Additionally, no 
change in the plasma ferritin level was observed between the mice administered with vehicle and the mice with 
BSA overload. Plasma iron and transferrin saturation (TSAT) were observed to be elevated in the BSA-treated 
mice. Plasma ferritin, plasma iron and TSAT levels were diminished in the BSA-treated mice with IRD. Plasma 
hepcidin-1 was also found to be elevated in the mice with BSA overload, which was dramatically reduced by IRD 
(Table 2).
Discussion
Proteinuria is an early biomarker for patients with CKD and a causal factor for the progression of CKD by elic-
iting tubular damage and tubulointerstitial injury. We first demonstrated that BSA overload enhanced ferrous 
iron levels in the kidney, although the renal total iron content was not altered. Renal iron content is increased 
in the mice with unilateral ureteral obstruction (UUO) surgery17 or in mice with 5/6 nephrectomy16, indicating 
that the increment in ferrous iron is due to the increase of total iron content. Furthermore, dietary iron reduction 
Figure 4. BSA-induced inflammasome activation inhibited in the kidneys of mice by dietary iron restriction. 
(a) Representative figures of nucleotide-binding oligomerisation domain-like receptor pyrin domain-containing 
protein 3 (NLRP3) staining in the kidneys of mice in each group. (b) NLRP3 mRNA expression in the kidneys 
of mice. Values are expressed as mean ± SD, *P < 0.05, **P < 0.01, n = 7–9 in each group. (c) Representative 
protein bands of NLRP3, caspase-1, ASC, IL-1β, and β-actin in the kidneys of mice (full-length blots are 
presented as Supplementary Figure 1). (d) Semiquantitative analysis of densitometry for NLRP3, mature 
caspase-1, ASC, and mature IL-1β in the kidney. Values are expressed as mean ± SD, *P < 0.05, **P < 0.01, 
n = 12 in each group.
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prevented the progression of diabetic nephropathy in the db/db mice, however, no difference was observed in the 
renal iron content of the control mice and that of the db/db mice12, suggesting the involvement of the labile fer-
rous iron, rather than the total iron content, in the pathological condition. In cisplatin-induced nephropathy and 
ischemia-reperfusion injury, bleomycin-detectable iron (iron capable of catalysing the reaction of free radicals 
is same as ferrous iron) and hydroxyl radical formation increased in the mice kidneys18, 19. It has been clinically 
observed that urinary catalytic iron increased during diabetic nephropathy or glomerulonephritis20. Thus, fer-
rous iron increased in these kidney diseases, and may be responsible for their pathological condition. Although 
the primary mechanism of ferrous iron augmentation remains unclear, labile ferrous iron is potentially involved 
Vehicle BSA BSA + IRD
Body weight (g) 23.4 ± 1.1 23.7 ± 1.7 24 ± 2
Right kidney weight (mg) 109 ± 7 131 ± 18** 129 ± 10**
Right kidney weight to body weight ratio 4.6 ± 0.2 5.5 ± 0.5** 5.4 ± 0.2*
Renal iron content (µg/g tissue) 9.9 ± 3.6 9.7 ± 3 5.4 ± 1.9*#
Red blood cell (×104/µL) 827 ± 63 829 ± 48 760 ± 49*#
Haemoglobin (g/dL) 12.6 ± 1 12.4 ± 0.7 10.6 ± 1.1**##
Haematocrit (%) 38.1 ± 3.3 38.1 ± 2 32.1 ± 3.1**##
MCV (fL) 46.1 ± 1 45.8 ± 1.1 42.4 ± 1.6**##
MCH (pg) 15.2 ± 3.3 15 ± 0.2 14 ± 0.6**##
MCHC (g/dL) 33 ± 0.7 32.6 ± 0.4 33.3 ± 0.4#
Table 1. Effects of bovine serum albumin (BSA) treatment and iron-restricted diet (IRD) on body weight, 
kidney weight, kidney iron content, red blood cell count, haemoglobin, haematocrit, mean corpuscular volume 
(MCV), mean corpuscular haemoglobin (MCH), and mean corpuscular haemoglobin concentration (MCHC) 
in mice. Data represent mean ± SD; n = 8 or 9; *P < 0.05, **P < 0.01 vs. control mice; #P < 0.05, ##P < 0.01 vs. 
BSA-treated mice.
Figure 5. The effect of BSA overload on ferrous iron in the kidney. Upper panels, representative figures of 
RhoNox-1 staining in kidneys in each group; lower panel, semiquantitative analysis of RhoNox-1 staining of 
kidneys in each group. Values are expressed as mean ± SD, **P < 0.01, n = 4 in each group.
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in different types of kidney injury, and BSA overload-mediated increase in ferrous iron can also be a trigger for 
causing renal tubulointerstitial injury.
Therefore, protein overload-induced increment in renal ferrous iron suggested the promotion of oxida-
tive stress via the Fenton reaction. As expected, renal superoxide and labile iron levels were reduced by IRD. 
Similar to this study, it has been observed that renal injuries induced by cisplatin or ischemia–reperfusion 
were diminished by iron chelation, through the inhibition of hydroxyl radical production, resulting in a 
decrease in the ferrous iron levels18, 21. In addition to the Fenton reaction, NADPH oxidase activity and p22phox 
expression was upregulated in the kidneys of mice with protein overload, which was inhibited by dietary iron 
restriction. Protein overload augments NADPH oxidase activity6. We demonstrated that iron reduction dimin-
ished NADPH oxidase activity and p22phox expression in diabetic nephropathy and renal fibrosis induced by 
unilateral ureteral obstruction12, 17. This supported the findings of our present study, since iron was essential 
for enzymatic activity of NADPH oxidase22 and biosynthesis of p22phox subunit, which is a haemprotein23. 
Therefore, protein overload causes oxidative stress through the iron-dependent Fenton reaction and NADPH 
oxidase in the kidney, and these changes were inhibited by iron reduction, contributing to the alleviation of 
BSA-induced tubulointerstitial injury.
Consistent with our study, other studies have reported that both pharmacological and dietary iron reduction 
ameliorated the progression of CKD in various disease models12–14, 16, 17. In the present study, BSA-induced tub-
ulointerstitial injury was diminished by iron restriction through the inhibition of oxidative stress, macrophage 
infiltration, inflammatory cytokines, and fibrosis-related genes. Oxidative stress is well-known to elicit an inflam-
matory response by activating transcription factors, such as NF-κβ24. Consistent with these findings, iron reduc-
tion has been known as an effective approach for reducing macrophage infiltration, inflammatory cytokines, and 
fibrosis in CKD such as diabetic nephropathy12–14, 5/6 nephrectomy16, and UUO-induced renal fibrosis17. This 
supports the inhibitory effect of iron restriction on renal tubulointerstitial injury induced by BSA overload by 
suppressing inflammation via reduced oxidative stress production.
The NLRP3 inflammasome plays a crucial role in regulating the caspase-1 activity and cleaving pro-IL-1β into 
its secreted form25. The NLRP3 inflammasome also contributes in promoting renal inflammation and CKD pro-
gression26 and implicates tubulointerstitial injury induced by protein overload7, 8. Similar to the above-mentioned 
studies, in the present study, BSA overload promoted NLRP3 inflammasome activation in the kidneys, which 
was suppressed by dietary iron restriction. Regarding the effect of iron on the inflammasome, cellular labile iron 
acts as a trigger for activating the NLRP3 inflammasome through iron-mediated reactive oxygen species (ROS) 
production in the macrophage27 and retina28. ROS is an upstream signalling molecule for NLRP3 inflammasome 
activation29. Collectively, the activation of NLRP3 inflammasome may be caused by ferrous iron-mediated oxida-
tive stress production via the Fenton reaction or NADPH oxidase activation in the kidney. Therefore, iron restric-
tion is also effective in inhibiting BSA-induced augmentation of renal ferrous iron, resulting in the suppression of 
NLRP3 inflammasome activation by reducing oxidative stress.
Among the biochemical parameters for determining iron status, the levels of plasma hepcidin-1 and TSAT 
were observed to be elevated in the mice with BSA overload. Hepcidin, a hormone secreted by hepatocytes, is an 
important regulator for iron metabolism. It acts by downregulating the expression of ferroportin, which is an iron 
exporter30. Patients with CKD display an elevated level of hepcidin31. Plasma hepcidin concentration, as well as 
mRNA levels of hepatic hepcidin, is also increased in adenine-induced CKD in mice32. Increased hepcidin level 
impairs the proper use for intracellular stored iron and the absorption of iron from the duodenum, resulting in 
the disturbance of systemic iron metabolism in CKD. Therefore, the increase in hepcidin level induced by BSA 
overload might also be involved in the alteration of iron homeostasis. Although TSAT was higher in BSA-treated 
mice, there was no difference of stored iron as indicated by plasma ferritin levels and renal iron concentration 
between vehicle-treated mice and BSA-treated mice, and plasma iron levels were elevated by BSA treatment, 
which disagree impaired utilization of iron regardless of hepcidin elevation. Further studies are needed to clarify 
the link between renal dysfunction and systemic iron homeostasis in CKD.
Patients with advanced CKD and end-stage renal dysfunction with renal anaemia are treated with the 
erythropoiesis-stimulating agent (ESA) along with iron, which is necessary for the effective functioning of ESA33. 
Further titration studies are necessary to clarify the optimal iron intake and iron status in CKD with respect to 
kidney function and hematopoiesis. In addition, iron deficiency is also known to stimulate fibroblast growth 
Vehicle BSA BSA + IRD
Plasma total protein (g/dL) 6.3 ± 1.2 9.2 ± 1.1** 9.2 ± 0.9**
Plasma albumin (g/dL) 2.8 ± 0.4 5.8 ± 0.9** 5.6 ± 1.1**
BUN (mg/dL) 29.2 ± 5.0 40.0 ± 9.8** 32.4 ± 5.7#
Plasma creatinine (mg/dL) 0.61 ± 0.08 0.61 ± 0.09 0.59 ± 0.09
Plasma ferritin (ng/mL) 814.2 ± 178.6 631.8 ± 170.0 323.2 ± 145.91**##
Plasma iron (µg/dL) 60.0 ± 7.3 78.2 ± 9.6** 61.9 ± 12.1##
TSAT (%) 25.1 ± 5.74 38.5 ± 6.8** 25.8 ± 8.3##
Plasma hepcidin-1 (ng/dL) 51.0 ± 33.8 112.6 ± 30.8** 0.4 ± 0.11*##
Table 2. Effects of bovine serum albumin (BSA) treatment and iron-restricted diet (IRD) on the levels of 
plasma total protein, plasma albumin, blood urea nitrogen (BUN), plasma creatinine, plasma ferritin, plasma 
iron, transferrin saturation (TSAT), and plasma hepcidin-1 in mice. Data represent mean ± SD; n = 5–13; 
*P < 0.05, **P < 0.01 vs. control mice; #P < 0.05, ##P < 0.01 vs. BSA-treated mice.
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factor 23 (FGF23), a bone-derived phosphaturic hormone. The level of FGF23 is elevated in patients with CKD. 
Such elevated FGF23 levels are independently associated with the progression of CKD, cardiovascular events, and 
mortality34. Therefore, the beneficial effects of IRD on CKD might be offset by an increase in the level of FGF23. 
Further investigation is required to elucidate the beneficial and adverse effects of iron restriction on CKD.
In conclusion, augmentation of ferrous iron induced by protein overload causes oxidative stress via the Fenton 
reaction and NADPH oxidase, resulting in renal tubulointerstitial injury and inflammatory changes, which are 
ameliorated by iron restriction. These observations indicate that iron-mediated oxidative stress results in the 
pathogenesis of protein overload-induced renal injury.
Materials and Methods
Materials. We purchased and used the following commercially available antibodies: anti-interleukin-1β, 
anti-ASC (apoptosis-associated speck-like protein containing a CARD), anti-caspase-1 (p10), anti-fibronectin 
(Santa Cruz Biotechnology, Inc., Dallas, TX), anti-NLRP3 (Cell Signalling Technology, Danvers, MA), anti-F4/80 
(Bio-Rad Laboratories, Hercules, CA), anti-type I collagen (SouthernBiotech, Birmingham, AL), and anti-β-actin 
(protein loading control, Cell Signalling Technology).
Animal preparation and procedure. All experimental procedures for mice were performed in accord-
ance with the guidelines of the Animal Research Committee of Tokushima University Graduate School, and the 
protocol was approved by the Institutional Review Board of Tokushima University Graduate School for animal 
protection (Permit Number: 14137). The mice were randomly divided into three groups: vehicle with normal 
diet (ND)-fed group, BSA with ND-fed group, and BSA with IRD-fed group. Seven-week-old male C57BL/6J 
mice were obtained from Nippon CLEA (Tokyo, Japan) and were maintained with ad libitum access to water 
and food. Then, mice were either fed with commercially available ND [D03072502 (3.9 mg Fe/100 g food)] or 
IRD [D03072501 (0.3 mg Fe/100 g food)] (Research Diets, Inc. New Brunswick, NJ). After 1 week, the mice were 
intraperitoneally injected with BSA. A stepwise increment dose regime of BSA was employed for inducing protein 
overload tubulointerstitial injury in the mice7. In brief, the initial BSA dose was 2 mg/g body weight on the first 
day and was increased gradually to the maximum dose of 10 mg/g body weight on day 5, which was maintained 
for 7 days. For the vehicle-treated group, the mice received intraperitoneal injection of normal saline. On day 12, 
24 h after the last BSA dose, the mice were euthanised by intraperitoneally injecting an overdose of pentobarbital, 
and kidneys were removed and stored at −80 °C until further use.
Preparation of BSA solution. BSA [Cohn fraction V (019–23293); Wako Pure Chemical Industries, Ltd., 
Osaka, Japan] was dissolved in normal saline, and the final concentration was 330 mg/mL. The concentration 
of endotoxin in BSA solution was 0.03 ng/mL, as detected by the limulus amebocyte lysate assay (Pierce™ LAL 
Chromogenic Endotoxin Quantitation Kit, Thermo Fisher Scientific, Inc., Waltham, MA).
Real-time PCR for mRNA quantification. RNA extraction, cDNA synthesis, and quantita-
tive RT-PCR methods have been described previously in detail12. In brief, the tissues were homog-
enised in the RNAiso reagent (TAKARA Bio, Inc., Otsu, Japan) using a Minilys tissue homogenizer 
(Bertin Instruments, Montigny-le-Bretonneux, France). RNA extraction and cDNA synthesis were per-
formed according to the manufacturer’s instructions [PrimeScript RT reagent kit with gDNA Eraser 
(Perfect Real Time); TAKARA Bio, Inc.]. Quantitative RT-PCR was performed using the CFX 
Connect Real-Time PCR Detection System (BIO-RAD Laboratories Inc., Hercules, CA, USA) with 
THUNDERBIRD SYBR qPCR Mix (TOYOBO CO., LTD., Osaka, Japan). The primer sets used were as fol-
lows: 5′- ACGGCATGGATCTCAAAGAC-3′ and 5′-GTGGGTGAGGAGCACGTAGT-3′ for TNF-α, 
5′-GGAGCTCATGATGTGAGCAA-3′ and 5′-GACCAGGCAAGGGAATTACA-3′ for monocyte chemotac-
tic protein-1 (MCP-1), 5′- CCGGAGAGGAGACTTCACAG-3′ and 5′-TCCACGATTTCCCAGAGAAC-3′ 
for IL-6 ,  5 ′-GAGCGGAGAGTACTGGATCG-3 ′  and 5 ′-GTTCGGGCTGATGTACCAGT-3 ′  for 
collagen-1, 5′-GTCTTTCCGACCAAGAGCAG-3′  and 5′-GACAAAGGCTGTGGAGGAAG-3′  for 
PAI-1, 5′-ACAGAGCTCAACCTCCCTGA-3′  and 5′-TGTGCTCCTGGTTCTCCT-3′  for fibronec-
tin ,  5′-CTGTAACCGGATGGCAAACT-3′  and 5′-CTGTACCCACATGGCTGATG-3′  for F4/80 , 
5 ′-  GTGGACTCCCAT TGAGCCTA-3 ′  and 5 ′-CTCCTCT TCACCCTCACTCG-3 ′  for p22phox, 
5′-TGGAAGAACCAAGGAGCTGT-3′ and 5′-GGTGGGGACAGAGAAGATGA-3′ for lipocalin-2, and 
5′-GCTCCAAGCAGATGCAGCA-3′ and 5′-CCGGATGTGAGGCAGCAG-3′ for 36B4 (internal control). The 
expression levels of all target genes were normalised using 36B4 expression, and the values were compared to the 
control group in terms of relative fold changes.
Protein extraction and western blot analysis. Protein preparation and western blotting were per-
formed as previously described12. In brief, kidney tissue samples were homogenised with the Minilys bead-based 
homogeniser (Bertin Instruments, Montigny-le-Bretonneux, France) and proteins were extracted. The extracted 
proteins were boiled for 5 min in the Laemmli sample buffer and separated using SDS–PAGE. Proteins were 
transferred onto a polyvinylidene fluoride (PVDF) membrane and the membrane was blocked for 1 h at room 
temperature. Next, the membrane was incubated individually with each primary antibody overnight at 4 °C, 
followed by incubation for 1 h with the secondary antibody. Then, immunoreactive bands were detected using a 
chemiluminescent reagent and visualised by exposure onto an X-ray film or by C-DiGit Blot Scanner (LI–COR, 
Lincoln, Nebraska, USA). Densitometry of the visualised bands was quantified using the Image J 1.38x software 
(https://imagej.nih.gov/ij/).
www.nature.com/scientificreports/
8SCIeNTIfIC REPORTS | 7: 10621  | DOI:10.1038/s41598-017-11089-0
Histological analysis for tubulointerstitial damage. The assessment of renal tubulointerstitial dam-
age has been described previously35. In brief, the kidney tissue samples were fixed in 4% paraformaldehyde and 
embedded in paraffin. Samples were cut into 3-µm sections, and the sections were stained with haematoxylin and 
eosin (HE). Tubular injuries were scored in a blinded manner according to the percentage of damage (including 
atrophy, flattening of the proximal tubule epithelial cells, and tubular dilation) as follows: 0, normal; 1, <20%; 2, 
20–40%; 3, 40–60%; 4, 60–80%, and 5, >80%. Ten random microscopic fields per kidney section were used for 
quantification.
Immunohistochemistry of the kidney samples. Immunohistochemical staining of F4/80 and fibronec-
tin was performed as described previously17. In brief, the paraffin-embedded kidney samples were cut into 3-µm 
sections, deparaffinised, processed for antigen retrieval using 10 mM citrate buffer at 95 °C for 20 min, and cooled 
for 20 min. For collagen-1 staining, the frozen tissue sections were used36. Non-fixed kidney tissues were embed-
ded in the Tissue-Tek O.C.T. Compound (Sakura Finetek, Tokyo, Japan) and subjected to snap freezing using the 
liquid nitrogen–cold isopentane mixture. Samples were cut into 8-µm sections, dried, and fixed in 10% neutral 
formaldehyde for 10 min. After blocking, the sections were incubated with the primary antibody at 4 °C overnight. 
Antibody distribution was visualised using a streptavidin–biotin complex assay and a 3,3′-diaminobenzidine 
(DAB) substrate kit (LSAB + Kit Universal; Dako Japan, Tokyo, Japan). Sections incubated without the primary 
antibody were used as negative controls. The evaluation of macrophage infiltration in tubulointerstitium was 
performed as described previously17. Briefly, ten microscopic fields were randomly selected in the renal cortex 
and the macrophage-positive area was expressed as a percentage of the total area, except the areas under tubular 
lumen, glomeruli, and vessels, using the ImageJ 1.38x software.
Measurement of tissue iron content. Tissue iron content was measured using an iron assay kit according 
to the manufacturer’s instructions (Metallo assay; Metallogenics Co., Ltd., Chiba, Japan), as described previ-
ously12, 17. In brief, the kidney tissue samples were homogenised in the cell lysis buffer, and the non-centrifuged 
crude lysates with 0.05 M hydrochloric acid were mixed at regular intervals for 30 min, and centrifuged with 
12,000 rpm for 10 min at 4 °C. Subsequently, the supernatants were used for assay. Tissue iron concentration was 
corrected using tissue weight and expressed as µg/g of wet tissue.
Measurement of NADPH oxidase activity. NADPH oxidase activity was measured as previously 
described12, 17. In brief, the kidney tissue sample was immediately homogenised in the NADPH oxidase lysis 
buffer and sonicated for 3 s. The NADPH substrate (final concentration, 300 µM) was added to the renal suspen-
sion with lucigenin (5 µM). Luminescence was measured every second for 60 min in a plate reader (SpectraMax 
Paradigm FilterMaxF3; Molecular Devices Japan, Tokyo, Japan). NADPH activity was expressed as relative lumi-
nescence units normalised to the protein concentration.
In situ oxidative stress detection in the kidney tissue. Detection of superoxide production in the 
kidney was evaluated by DHE staining method as previously described12. Non-fixed frozen tissue sections were 
washed with PBS, incubated with DHE in PBS (10 µM) in a dark, humidified container at room temperature for 
30 min, and observed using fluorescence microscopy.
Detection of renal ferrous iron. RhoNox-1 was used to detect ferrous iron content in the kidney37. The 
staining method used has been described previously36. First, frozen sections were washed three times in Hank’s 
balanced salt solution (HBSS) for 5 min, fixed in 10% neutral formaldehyde for 1 min, and washed three times 
with HBSS for 5 min. Next, the fixed sections were incubated with RhoNox-1 in HBSS (5 µM) in a dark, humid-
ified container at room temperature for 30 min. After washing three times with HBSS, the sections were covered 
with a small drop of the mounting medium and observed using fluorescence microscopy. The section stained with 
RhoNox-1 was observed and quantified using fluorescence microscopy.
Haematological and biochemical analysis. Peripheral blood samples were analysed at Shikoku Chuken, 
K.K. (Kagawa, Japan). The plasma total protein concentration was measured by the bicinchoninic acid assay 
(BCA) assay. The analysis of plasma albumin, BUN, and TSAT was performed at the Nagahama Life Science 
Laboratory (Shiga, Japan). The plasma creatinine level was measured using the LabAssay Creatinine kit (Wako 
Pure Chemical Industries, Ltd., Osaka, Japan). The plasma ferritin concentration was determined using the 
Mouse Ferritin ELISA kit (Immunology Consultants Laboratory, Newberg, OR) according to the manufacturer’s 
instructions. The hepcidin-1 concentration in mice was measured using surface-enhanced laser desorption/ion-
ization time-of-flight mass spectrometry (SELDI-TOF–MS38; Medical Care Proteomics Biotechnology Co., Ltd., 
Kanazawa, Japan).
Statistical analysis. Data are presented as mean ± standard deviation (SD). Significant differences between 
the three groups were determined using one-way ANOVA followed by Tukey’s post-hoc test. The differences 
between data were considered to be statistically significant at P < 0.05.
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